Disease modifying antirheumatic drugs taken by the experimental (A) and 31 control (B) patients with early RA. The percentage of patients taking each drug or combination over 5 years is shown. INFL, infliximab; COMBO+MTX, combination of DMARDs including methotrexate; DMARD, disease modifying antirheumatic drug; MTX, methotrexate; COMBO–MTX, combination of DMARDs without methotrexate; SSZ, sulfasalazine; MYO, intramuscular gold; HCQ, hydroxychloroquine.